On June 4, 2019, Theravance Biopharma, Inc. (the Company) announced the appointment of Andrew Hindman as Senior Vice President and Chief Financial Officer. Mr. Hindman, age 46, has held several senior executive level positions in the biopharmaceutical industry, most recently as Chief Business Officer of Acorda Therapeutics since March 2018 and prior to that role he served as Chief Business Development Officer from May 2014 to March 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.12 USD | +0.22% | -2.88% | -18.86% |
May. 13 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
May. 13 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.86% | 444M | |
+37.78% | 723B | |
+31.54% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.42% | 244B | |
-4.62% | 208B | |
+10.18% | 210B | |
+9.32% | 169B |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Theravance Biopharma, Inc. Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer